IL-17 Antagonist IV Dosing for Structural Damage Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current dosing regimens for IL-17 antagonists like secukinumab, such as Cosentyx®, are inconvenient due to their fixed dose and require multiple initial administrations, lacking flexibility and not suitable for heavier patients or those who cannot tolerate subcutaneous injections, and do not effectively prevent structural joint damage in autoimmune diseases like psoriatic arthritis and axial spondyloarthritis.
Innovation Solution
A flexible dosing regimen involving intravenous administration of IL-17 antagonists, such as secukinumab, with a loading dose of about 4 mg/kg to 9 mg/kg followed by monthly maintenance doses of 2 mg/kg to 4 mg/kg, tailored for patients with autoimmune diseases like psoriatic arthritis and axial spondyloarthritis, including non-radiographic axial spondyloarthritis and ankylosing spondylitis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If fixed dose subcutaneous dosing is used, then ease of operation is improved, but adaptability deteriorates
Solution Approach 1:
The patent transitions from fixed subcutaneous dosing to flexible intravenous dosing with variable dosing regimens (loading dose followed by maintenance doses at different intervals) that can be dynamically adjusted based on patient response, disease severity, and individual needs, thereby improving adaptability while maintaining ease of administration
Solution Approach 2:
The patent changes the dosing parameters from fixed subcutaneous injections to flexible intravenous dosing with variable dose amounts (e.g., 100-600 mg loading dose, then 100-300 mg maintenance doses) and variable dosing intervals (every 2-8 weeks), allowing customization for different patient populations including heavier patients and those who cannot tolerate subcutaneous injections
2Reliability
If multiple initial administrations are required, then treatment effectiveness is improved, but loss of time increases
Solution Approach 1:
The patent employs a loading dose administered before maintenance doses to achieve rapid therapeutic effect, allowing the drug to reach effective concentrations quickly in the initial phase, thereby maintaining treatment effectiveness while reducing the overall treatment time required to achieve clinical benefit
Solution Approach 2:
The patent uses periodic dosing regimens with flexible intervals (every 2-8 weeks) where the dosing frequency can be adjusted based on patient response, allowing intensive initial dosing followed by less frequent maintenance dosing, thus balancing treatment effectiveness with time efficiency
3Ease of operation
If subcutaneous injection is used, then ease of operation is improved, but adaptability deteriorates
Solution Approach 1:
The patent offers dynamic routing options between subcutaneous and intravenous administration, allowing clinicians to select the most appropriate route based on patient-specific factors such as injection tolerance, disease severity, and treatment setting, thereby improving adaptability while maintaining ease of operation through the availability of both convenient subcutaneous and effective intravenous options
Data Source
AI summary
The present disclosure relates to methods for treating patients having autoimmune diseases, e.g., methods for treating psoriatic arthritis (PsA) or axial spondyloarthritis (axSpA), e.g., non-radiographic axial spondyloarthritis (nr-axSpA) or ankylosing spondylitis (AS), using IL-17 antagonists, e.g., IL-17 antibodies, such as secukinumab. Also disclosed herein are methods for inhibiting the progression of structural damage in PsA and axSpA patients using IL-17 antagonists, e.g., IL-17 antibodies, such as secukinumab. The present disclosure also provides medicaments, pharmaceutical formulations, dosage forms, and kits for use in the disclosed methods.